Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Riassunto: BeOne Medicines, BeOne Care Foundation e The Max Foundation rinnovano la collaborazione per ampliare l'accesso a BRUKINSA® per il trattamento della leucemia linfatica cronica nei Paesi a reddito medio-basso

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines, in partnership with the BeOne Care Foundation and The Max Foundation, has renewed its collaboration until 2028 to enhance access to BRUKINSA® for chronic lymphocytic leukemia treatment. This initiative targets low-to-middle-income countries, aiming to improve healthcare outcomes in these regions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Renewed collaboration aims to improve access to BRUKINSA®.
  • Partnership includes reputable organizations like BeOne Care Foundation.
  • Focus on treating chronic lymphocytic leukemia in low-to-middle-income countries.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif. e SEATTLE--(BUSINESS WIRE)--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda multinazionale operante nel settore dell'oncologia, in collaborazione con la BeOne Care Foundation, una fondazione benefica no-profit, e The Max Foundation, importante ente sanitario internazionale non a scopo di lucro, oggi hanno annunciato di aver rinnovato la collaborazione fino al 2028 per estendere l'accesso a BRUKINSA® (zanubrutinib) per il trattamento della leuce

Frequently Asked Questions

What is BRUKINSA® used for?

BRUKINSA® (zanubrutinib) is used for treating chronic lymphocytic leukemia.

Who are the partners in this collaboration?

The partners include BeOne Medicines, BeOne Care Foundation, and The Max Foundation.

How long is the collaboration renewed for?

The collaboration has been renewed until 2028.

What regions does this initiative target?

The initiative targets low-to-middle-income countries.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines BRUKINSA chronic lymphocytic leukemia BeOne Care Foundation The Max Foundation
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →